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We conducted a nested case-control study to prospectively evaluate the relationship of serum
estrogens and androgens to risk of breast cancer in postmenopausal women. From 1977 to 1987,
3375 postmenopausal women free of cancer and not taking replacement estrogens donated blood
to the Breast Cancer Serum Bank in Columbia, Missouri. Of these, 72 were subsequently
diagnosed with breast cancer. For each case, two controls matched on age and date and time of
day of blood collection were selected using incidence density matching. The median age of
subjects at blood collection was 62 years; the time from blood collection to diagnosis ranged
from less than 1 to 9.5 years with a median of 2.9 years. Risk of breast cancer was positively and
significantly associated with serum levels of estrogens and androgens. Compared to women in
the lowest quartile, those in the highest quartile for non-sex hormone-binding globulin (non-
SHBG) bound (bioavailable) estradiol had a relative risk of 5.2 (95% confidence interval [CII =
1.5-18.5) and those in the highest quartile for testosterone had a relative risk of 6.2 (95% Cl =
2.0-19.0). Our results lend considerable support to the hypothesis that serum concentrations of
estrogens and androgens are related to the subsequent diagnosis of breast cancer in
postmenopausal women. Environ Health Perspect 105(Suppl 3):583-585 (1997)
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Introduction
Considerable data indicate that sex
hormones play a major role in the etiol-
ogy of breast cancer. Breast tumors fre-
quently are hormonally dependent and a
woman's reproductive history affects her
risk (1). However, results ofprospective
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epidemiologic studies that have evaluated
the relationship ofserum sex hormones to
breast cancer have been inconsistent. In
the largest prospective study of serum
estrogens and postmenopausal breast
cancer to date, Toniolo (2) reported
significant positive associations of serum
estradiol and estrone with risk. Berrino (3)
also recently reported significantly higher
serum testosterone levels among women
who subsequently developed breast cancer.
Nonsignificant excess risks ofbreast cancer
among postmenopausal women with ele-
vated serum estradiol, testosterone, and
androstenedione also were reported by
Helzlsouer (4). Others, however, have
found no association between serum sex
hormones and breast cancer risk (5,6). To
further evaluate relationship of serum
estrogens and androgens with breast cancer
in postmenopausal women, we performed
a prospective nested case-control study
using the Columbia, Missouri Breast
Cancer Serum Bank. This report summa-
rizes our findings, which were published in
their entirety in Cancer Epidemiology,
Biomarkers, andPrevention(7).
Methods
The Breast Cancer Serum Bank, Columbia,
Missouri, was established as part of the
National Cancer Institute's Biological
Markers Project to identify serum markers
for breast cancer. A total of7224 women
who initiallywere free ofbreast cancer vol-
unteered to donate blood and provide clin-
ical information to the bank between 1977
and 1987. Follow-up by mail continued
until 1989; but at least partly because of
funding changes, 70% ofthe women were
last contacted in 1982 to 1983. Informed
consentwas obtained from all women.
Women were eligible for the current
study if they had at least 4 ml of blood
remaining in the bankand if, at the time of
blood collection, they had no history of
cancer other than nonmelanoma skin
cancer, were not diagnosed with benign
breast disease within the previous 2 years,
were postmenopausal, and did not report
taking replacement estrogens. Ofthe 3375
women who met these criteria, 72 were
diagnosed with histologically confirmed
breast cancer. For each ofthese cases, two
controls were selected from among the eli-
gible women, using incidence density sam-
pling. Controls were alive and free of
cancer (except nonmelanoma skin cancer)
at the age ofthe case's diagnosis and were
matched to the case on exact age and on
date (± 1 year) and time (±2 hr) ofblood
draw. Following review of hormone
results, one case and four controls were
dropped because their follicle stimulating
hormone (FSH) values indicated that they
were premenopausal and one control was
dropped because her hormone profile was
consistent with exogenous estrogen use.
That left 66 case-control sets with two
controls and 5 case-control sets with one
control for analysis.
Serum was stored at -70°C until
analysis. Hormones were measured using
commercially available radioimmunoassay
(RIA) kits as follows: estradiol and testos-
terone (Diagnostic Products Co., Los
Angeles, CA); estrone and androstenedione
(Diagnostic Systems Labs, Webster, TX);
dehydroepiandrosterone sulfate (DHEAS)
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(ICN Biomedical, Costa Mesa, CA). Estrone
sulfate also was measured by RIA after
solvolysis, extraction ofhydrolyzed estrone,
and celite chromatography (8). Percent
unbound and albumin-bound estradiol were
measured using centrifugal ultrafiltration
(9), and sex hormone-binding globulin
(SHBG)-bound estradiol was calculated.
The relationship between serum
hormones and breast cancer risk for the
matched sets were evaluated using condi-
tional logistic regression (10). Women
were stratified into quartiles based on their
hormone levels relative to the distribution
ofhormone values in controls, and a set of
categorical (dummy) variables was induded
in models. To test for trends, models also
were fit using quartile medians. Models
also included time since menopause,
height, weight, parity, and family history
ofbreast cancer.
Results
Median ages of cases and controls at the
time ofblood collection were 61 and 62
years, respectively; and except for one con-
trol, all study subjects were white. Both
cases and controls had a median age at
menopause of 50 years. A slightly larger
proportion ofcases (20%) than controls
(14%) were nulliparous. The median
height ofcases was 163 cm. This was signi-
ficantly (p= 0.02) taller than controls,
whose median height was 160 cm. Weights
ofcases and control did not differ, nor did
their body mass indexes, which had a
median of26.0 for cases and 25.2 for con-
trols. The proportions ofcases and controls
with a family history ofbreast cancer also
did not differ. The median time from
blood collection to diagnosis of breast
cancer was 2.9 years with a range ofless
than 1 to 9.5 years.
As shown in Table 1, cases had higher
mean serum levels ofmost hormones mea-
sured compared to controls, and differences
were significant for androstenedione and
testosterone. Analysis ofrelative risk (RR)
also suggests relationship ofserum estrogens
and androgens with breast cancer. Women
in the upper three quartiles ofnon-SHBG-
bound estradiol had a 5-fold excess risk of
breast cancer relative to women in the lowest
quartile (Table 2). Similarly, women in the
third and fourth (highest) quartiles oftestos-
terone had RRvalues of2.9 and 6.2, respec-
tively. Asignificant trend ofincreasing breast
cancer risk with increasing androstenedione
level also was apparent. Although women in
the highest quartile for DHEAS also were at
a significantly elevated risk, there was no
Table 1. Geometric mean (±SD) levels of serum hormones in cases and controls.
Cases, Controls,
n=71 n=133 pValuea
Estradiol, pmol/liter 56.7 ± 4.4 48.6 ± 4.0 0.17
Non-SHBG bound estradiol, pmol/liter 25.8 ± 2.3 21.3 ± 1.9 0.13
Estrone, pmol/liter 127.5 ± 6.6 119.8 ± 5.2 0.38
Estrone sulfate, pmol/liter 510.4 ± 32.6 547.7 ± 28.3 0.41
Testosterone, nmol/liter 0.75 ± 0.07 0.55 ± 0.04 0.01
Androstenedione, nmol/literb 3.52 ± 1.6 2.97 ± 1.5 0.02
DHEAS, pmol/liter 2.41 ± 0.21 2.01 ± 0.11 0.08
'pValue (2-sided)from Student's t-test. bOne matched setdeleted because casewas an influential outlier.
Table 2. Numbers of subjects and adjusted relative risksa (95% confidence intervals) of breast cancer by quartile
ofserum estrogens and androgens.
Quartile
Hormone 1 (low) 2 3 4(high) Trend-p
Estradiol
(No. cases, no. controls) (6,32) (24,31) (26,36) (15,34)
Adjusted RR (95%Cl) 1.0 4.9(1.6-14.9) 4.7 (1.5-14.3) 2.7(0.8-9.1) 0.12
Non-SHBG-bound estradiol
(No. cases, no.controls) (5,33) (24,33) (23,33) (19,34)
Adjusted RR (95%CI) 1.0 5.9(1.8-19.3) 4.8(1.5-15.7) 5.2(1.6-18.5) 0.12
Estrone
(No. cases, no. controls) (14,31) (17,34) (16,34) (24,34)
Adjusted RR (95%Cl) 1.0 1.2(0.5-3.3) 1.0(0.4-2.9) 1.8(0.6-5.1) 0.36
Estrone sulfate
(No. cases, no. controls) (19,33) (19,33) (17,33) (16,34)
Adjusted RR (95%Cl) 1.0 0.8(0.3-2.1) 0.8(0.2 -2.2) 0.8(0.3-2.2) 0.58
Testosterone
(No. cases, no. controls) (9,32) (13,28) (20,39) (29,34)
Adjusted RR (95%Cl) 1.0 2.9(0.9-9.4) 2.9(1.0-8.6) 6.2(2.0-19.0) 0.002
Androstenedione
(No. cases, no. controls) (10,30) (20,34) (20,35) (21,34)
Adjusted RR (95%Cl) 1.0 1.7(0.6-4.7) 2.0(0.8-5.3) 2.2(0.8-5.8) 0.02b
DHEAS
(No. cases, no. controls) (13,33) (19,31) (8,34) (31,35)
Adjusted RR (95%Cl) 1.0 1.6(0.6-4.1) 0.6(0.2-1.9) 2.8(1.1-7.4) 0.05
'Cases and controls were matched on age, time, and year of blood collection and models included years since
menopause, height, weight, family history of breast cancer, and parity. bOne matched set deleted for trend test
because case was an influential outlier.
trend in risk ofbreast cancer with increasing
level ofthis hormone.
To evaluate whether higher serum
hormone levels in cases might be an effect
rather than a cause ofthe cancer, we strati-
fied cases into those diagnosed within 2
years ofblood collection (n=25) and those
diagnosed more than 2 years aftercollection
(n=46). Except for testosterone, relation-
ships between serum hormones and breast
cancer did not differ markedly between the
two groups. For testosterone, unadjusted
RR among the women diagnosed close in
time to blood collection were 2.5 (95% CI
= 0.6-11.2) and 4.1 (95% CI = 0.9-18.0),
respectively, for the middle and upper
tertiles. Comparable RR values for the
women diagnosed further in time from
collection were 1.0 (95% CI = 0.4-2.7) and
1.3 (95% CI = 0.5-3.4).
Discussion
Results ofthis prospective study provide
strong support for a relationship between
serum sex hormone levels and the subse-
quent development ofbreast cancer in post-
menopausal women. Women in the upper
three quartiles ofestradiol were at an ele-
vated risk ofbreast cancer. The relationship
was more consistent for non-SHBG-bound
estradiol, the fraction that is biologically
available, than for total estradiol. Serum lev-
els ofthe androgens, testosterone, androste-
nedione, and DHEAS, all were positively
associated with breast cancer risk. The asso-
ciation was strongest for testosterone, but we
could not discern whether that association
was a cause or an effect ofthe malignancy.
Additional studies are needed to determine
how serum hormone levels modify breast
cancerriskinpostmenopausal women.
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